Literature DB >> 11752224

Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response.

Yan Zhou1, Geetha Achanta, Helene Pelicano, Varsha Gandhi, William Plunkett, Peng Huang.   

Abstract

(E)-2'-deoxy-2'-(fluoromethylene)cytidine (FMdC) is a new analog of deoxycytidine with promising anticancer activity. We investigated the action of FMdC on DNA metabolism by evaluating its incorporation into DNA, its excision from DNA in vitro, and the role of the incorporation of FMdC into DNA in causing cytotoxicity. In vitro DNA primer extension demonstrated that FMdC nucleotides were incorporated with relatively high substrate efficiency into the C sites of the elongating DNA strand. Once incorporated, FMdC became a poor substrate for further chain elongation by DNA polymerases, resulting in a termination of DNA synthesis at the sites of incorporation. Furthermore, the 3' --> 5' exonuclease activity of DNA polymerase epsilon or wild-type p53 protein was ineffective in removing the incorporated FMdC from DNA in vitro. FMdC also showed potent cytotoxic activity against human leukemia and solid tumor cells. Incubation with a low concentration of FMdC (10 nM) induced cell cycle arrest at S or G1 phases, but the cells eventually died as the time of incubation increased. Compared with HL-60 cells, human myeloid ML-1 cells with wild-type p53 were more sensitive to FMdC, but the S or G1 phase arrest did not seem to depend on the presence or absence of p53. Inhibiting the incorporation of FMdC into cellular DNA by aphidicolin suppressed the cytotoxic effect of the compound. We conclude that the incorporated FMdC nucleotide profoundly disrupts DNA synthesis and resists excision by exonucleases, and that incorporation of this analog into DNA is a key molecular event responsible for the drug's cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11752224     DOI: 10.1124/mol.61.1.222

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Physical and functional interactions of the tumor suppressor protein p53 and DNA polymerase alpha-primase.

Authors:  Christian Melle; Heinz-Peter Nasheuer
Journal:  Nucleic Acids Res       Date:  2002-04-01       Impact factor: 16.971

2.  Excision of nucleoside analogs from DNA by p53 protein, a potential cellular mechanism of resistance to inhibitors of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Mary Bakhanashvili; Elena Novitsky; Ethan Rubinstein; Itzchak Levy; Galia Rahav
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 3.  Ribonucleotide Reductases: Structure, Chemistry, and Metabolism Suggest New Therapeutic Targets.

Authors:  Brandon L Greene; Gyunghoon Kang; Chang Cui; Marina Bennati; Daniel G Nocera; Catherine L Drennan; JoAnne Stubbe
Journal:  Annu Rev Biochem       Date:  2020-06-20       Impact factor: 23.643

4.  Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate.

Authors:  Yumin Hu; Weiqin Lu; Gang Chen; Hui Zhang; Yu Jia; Yue Wei; Hui Yang; Wan Zhang; Warren Fiskus; Kapil Bhalla; Michael Keating; Peng Huang; Guillermo Garcia-Manero
Journal:  Blood       Date:  2010-06-21       Impact factor: 22.113

Review 5.  Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

Authors:  Sarah E Huff; Jordan M Winter; Chris G Dealwis
Journal:  Biomolecules       Date:  2022-06-10

6.  Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.

Authors:  H Zhang; D Trachootham; W Lu; J Carew; F J Giles; M J Keating; R B Arlinghaus; P Huang
Journal:  Leukemia       Date:  2008-04-03       Impact factor: 11.528

7.  Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.

Authors:  Peiting Zeng; Wenhua Lu; Jingyu Tian; Shuang Qiao; Jiangjiang Li; Christophe Glorieux; Shijun Wen; Hui Zhang; Yiqing Li; Peng Huang
Journal:  J Hematol Oncol       Date:  2022-03-21       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.